Imbalance in the blood antioxidant system in growth hormone-deficient children before and after 1 year of recombinant growth hormone therapy

Abstract

The aim of our study was to examine the effects of 12-month therapy with recombinant growth hormone (rGH) on the blood antioxidant system in children with growth hormone deficiency (GHD). Total antioxidant capacity (TAC) of plasma was measured by FRAP (ferric reducing antioxidant power or ferric reducing ability of plasma); activities of superoxide dismutase (SOD) and catalase (CAT) in erythrocytes were assessed; non-protein thiols (NT) and ceruloplasmin (CP) levels were also measured. These parameters were determined before and after 12 month of rGH treatment. Eleven treatment-naive prepubertal children with growth hormone deficiency were included in the study. Another 11 prepubertal children comprised a control group. Before rGH treatment, TAC of plasma and NT level in the control group were significantly lower (726 ± 196 vs. 525 ± 166 µmol/L, P = 0.0182 and 0.92 ± 0.18 vs. 0.70 ± 0.22 µmol/ml, P = 0.0319, before and after the therapy, respectively). The only parameter that significantly (19.6 ± 4.7 vs. 14.5 ± 3.4 Units/g Hb, P = 0.0396) exceeded the same in the control group after rGH therapy was SOD activity. However, none of the measured parameters of antioxidant system in GHD children, except for TAC (525 ± 166 vs. 658 ± 115 µmol/L, P = 0.0205), exhibited significant improvement toward the end of the 12-month treatment period, although non-significant changes in CAT activity and CP level were also observed. This work has demonstrated that some parameters of the blood antioxidant system are out of balance and even impaired in GHD children. A 12-month treatment with rGH resulted in a partial improvement of the antioxidant system.

Sexual Dimorphism of Heart Rate Variability in Adolescence: A Case-Control Study on Depression, Anxiety, Stress Levels, Body Composition, and Heart Rate Variability in Adolescents with Impaired Fasting Glucose

“…Additionally, a surge of growth hormone is observed in adolescence. Growth hormone is responsible for the growth spurt but it also exhibits antioxidant properties [35] that possibly, even if it provokes insulin resistance [36], counterbalances the pro-oxidative processes of hyperglycemia [37]. Regrettably, no such studies exist in adolescents.…”

On elucidation of the role of mitochondria dysfunction and oxidative stress in multiple sclerosis

“…Mycoplasma pneumonia, a bacteria linked to MS, promotes OS . Lower growth hormone (GH) has been observed in patients with more severe MS, and numerous lines of evidence suggest that GH attenuates OS …”

“…240 Lower growth hormone (GH) has been observed in patients with more severe MS, 241 and numerous lines of evidence suggest that GH attenuates OS. [242][243][244] Fatigue is common in MS. 245 MtD has been implicated in the fatigue observed in many chronic diseases including MS 246 and CoQ10; microencapsulated NADH, l-carnitine, and α-lipoic acid can be used to restore mitochondrial function and attenuate fatigue in patients with chronic illnesses. 246 Evidence suggests that fatigue is a key feature of mitochondrial disease 247 and mitochondria bioenergetics is altered in patients with chronic fatigue syndrome.…”

Promising methods for noninvasive medical diagnosis based on the use of nanoparticles: surface-enhanced raman spectroscopy in the study of cells, cell organelles and neurotransmitter metabolism markers

“…When studying red blood cells, one should bear in mind that SERS spectra can be obtained only from cytoplasmic Hb (Hb cyt ), which constitutes the largest proportion of total Hb, but not from membrane-bound Hb (Hb mb ) whose conformation can change in patients with blood diseases, hereditary or endocrine disorders (thalassemia, hemoglobinopathy, etc.) [69], intoxication, or under extreme conditions [70]. In those cases, signal enhancement is caused by Hb mb located in close proximity to silver nanostructures.…”